Riskpilot← Back to searchSign inGet full accessNORWEGIAN PHARMACY AS
ASActiveOrg 923767711Hattemakerlia 153, 2019 SkedsmokorsetRetail sale of pharmaceutical products · NACE 4773Est. 201927 employees
Revenue 2025
NOK 86,3M
+85% vs 2024
EBITDA margin
-3.2%
+16% vs 2024
Equity ratio
1.3%
Financial strength
Net profit 2025
NOK -3,7M
+14% vs 2024
| Revenue | NOK 86,3M | +85% |
| EBITDA | NOK -2,7M | +16% |
| Net profit | NOK -3,7M | +14% |
| Total assets | NOK 15,1M | +37% |
| Equity | NOK 203K | +18% |
| Employees | 27 | — |
Legal name
NORWEGIAN PHARMACY AS
Org number
923767711
Legal form
Aksjeselskap
NACE code
4773 · Retail sale of pharmaceutical products
Founded
5. november 2019
Share capital
NOK 30 000
Employees
27 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Styrets medlemmer hver for seg.
Company purpose
Eie og drive apotek, herunder konsulenttjenester innenfor apotekbransjen og lege- og helserelaterte produkter, samt øvrig virksomhet i tilknytning til dette.
Address
Hattemakerlia 153, 2019 Skedsmokorset
Phone
+4722992929
Email
kundeservice@apotekfordeg.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 2 208 | 33 543 | 64 403 | 46 741 | 86 262 |
| Staff expenses | −1 406 | −3 353 | −6 484 | −6 266 | −7 051 |
| EBITDA | 65 | −13 000 | −6 051 | −3 247 | −2 737 |
| Depreciation & amort. | −57 | −530 | −929 | −979 | −951 |
| EBIT | 8 | −13 530 | −6 980 | −4 226 | −3 688 |
| Net financials | −3 | −10 | −96 | −57 | 0 |
| Profit before tax | 6 | −13 540 | −7 076 | −4 283 | −3 688 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | 6 | −13 540 | −7 076 | −4 283 | −3 688 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 746 | 9 538 | 17 271 | 11 059 | 15 114 |
| Equity | 530 | 91 | 114 | 172 | 203 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 215 | 9 448 | 17 156 | 10 887 | 14 912 |
| Total debt | 215 | 9 448 | 17 156 | 10 887 | 14 912 |
EBITDA margin
-3.2%
This company
15.8%
Market median
-120% vs market
20212025
Equity ratio
1.3%
This company
38.2%
Market median
-97% vs market
20212025
Return on equity
-1821.0%
This company
18.4%
Market median
-9997% vs market
20212025
Net profit margin
-4.3%
This company
8.1%
Market median
-153% vs market
20212025
Asset turnover
5.71×
This company
1.12×
Market median
+410% vs market
20212025
Debt / equity
73.63×
This company
0.62×
Market median
-11776% vs market
20212025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2019 | |
| Chairman | 2019 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Pharma Active As
NORWEGIAN PHARMACY AS Board members of NORWEGIAN PHARMACY AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Huu Erica Thien Khuong | Board of Directors | 0 companies |
| Martin Le | Chairman | 0 companies |